The development of COVID-19 treatment
Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Therapeutic advances in COVID-19
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
CR Wolfe, KM Tomashek, TF Patterson… - The lancet respiratory …, 2022 - thelancet.com
Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
Small molecules in the treatment of COVID-19
S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
societies and economies. Until now, effective therapeutics against COVID-19 are in high …
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
O Abani, A Abbas, F Abbas, J Abbas, K Abbas… - The Lancet, 2022 - thelancet.com
Background We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor,
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …
for the treatment of patients admitted to hospital with COVID-19. Methods This randomised …
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
S Cajander, M Kox, BP Scicluna… - The Lancet …, 2024 - thelancet.com
Sepsis is characterised by a dysregulated host immune response to infection. Despite
recognition of its significance, immune status monitoring is not implemented in clinical …
recognition of its significance, immune status monitoring is not implemented in clinical …
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
T Marjot, CS Eberhardt, T Boettler, LS Belli… - Journal of …, 2022 - Elsevier
The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …
particularly healthcare professionals and patients. While the rapid development of safe and …
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness
P Pandharipande, SW Roberson… - The Lancet …, 2023 - thelancet.com
Despite advances in the treatment and mitigation of critical illness caused by infection with
SARS-CoV-2, millions of survivors have a devastating, post-acute infection syndrome known …
SARS-CoV-2, millions of survivors have a devastating, post-acute infection syndrome known …